Across TCGA pan-cancer cohorts, DAP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DAP data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DAP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DAP expression acts as an unfavorable survival marker.
STAD, ACC, and SKCM are the cancer types where DAP Mutation most reproducibly stratifies survival.